Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

Lung Clinical Trials

Narrow List by Age:

(Refer to Clinical Summary for age requirements)

Lung

Protocol Alliance A081105
Cancer Type: Non-Small Cell Lung
Fast Facts

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

A substudy of ALCHEMIST A151216

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG LU006
Cancer Type: MALIGNANT PLEURAL MESOTHELIOMA

PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol ECOG E4512
Cancer Type: Non-Small Cell Lung
Fast Facts

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A substudy of ALCHEMIST A151216

Protocol EA5162
Cancer Type: Advanced NSCLC
Fast Facts

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

Protocol EA5163
Cancer Type: Non-Small Cell Lung Cancer (NSCLC)
Fast Facts

A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

Protocol EA5181
Cancer Type: NSCLC
Fast Facts

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Protocol NRG LU002
Cancer Type: METASTATIC NON-SMALL CELL LUNG CANCER
Fast Facts

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Protocol SWOG S1400F
Cancer Type: Lung Cancer
Fast Facts

A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTI-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)

Protocol SWOG S1900A
Cancer Type: NSCLC
Fast Facts

A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Protocol SWOG S1900B
Cancer Type: NSCLC
Fast Facts

A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Protocol NRG LU003
Cancer Type: ALK Positive Non Squamous NSCLC

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol

Protocol SWOG S1914
Cancer Type: Early Stage NSCLC
Fast Facts

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Protocol Alliance A081801
Cancer Type: resected NSCLC
Fast Facts

Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO

Protocol EA5191
Cancer Type: NSCLC
Fast Facts

 A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG CC003
Cancer Type: SCLC
Fast Facts

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Protocol NRG LU005
Cancer Type: Limited Stage Small Cell Lung Cancer
Fast Facts

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Protocol SWOG S1827
Cancer Type: Small Cell Lung
Fast Facts

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI):  A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Protocol SWOG S1929
Cancer Type: ES-SCLC
Fast Facts

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Protocol NRG LU007
Cancer Type: ES-SCLC
Fast Facts

 RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC:  RAPTOR trial

Please check out the rare protocol list to locate other studies within this disease site.

Protocol ACCRU 2018-01
Cancer Type: Untreated Solid Tumors
Fast Facts

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors

Protocol PDM 9846
Cancer Type: Tissue Procurement
Fast Facts

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1714
Cancer Type: Multiple Cancer control
Fast Facts

A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A151216
Cancer Type: Non-Small Cell Lung
Fast Facts

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sub-Studies to ALCHEMIST: A081105,  E4512 and EA5142

Protocol LUNG MAP
Cancer Type: NSCLC
Fast Facts

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.